Hence, senolytics that clear senescent cells or mTOR inhibitors that hinder PI3K/mTOR pathway activation can play a therapeutic role in lung cancer patients, including those with COPD. The gene discussed is MTOR; the disease is chronic obstructive pulmonary disease.